Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue. The post Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs appeared first on MedCity…
When the catastrophic Los Angeles fires broke out, John Volckens suspected firefighters and residents were breathing toxic air from the burning homes, buildings, and cars, but it was unclear how much risk the public faced. So, the professor of environmental health at Colorado State University devised a plan to get answers. Volckens shipped 10 air…
Within days of Donald Trump’s election victory, health care entrepreneur Calley Means turned to social media to crowdsource advice. “First 100 days,” said Means, a former consultant to Big Pharma who uses the social platform X to focus attention on chronic disease. “What should be done to reform the FDA?” The question was more than…
This policy watch examines state-by-state school vaccine requirements and exemptions, including recent policy changes to them and the extent to which they may affect vaccination rates.
[Sponsored] Cold and heat therapy remain foundational tools in musculoskeletal care, postoperative recovery and sports rehabilitation. The post Top-Rated Gel Packs for Physical Therapy: Best Brands and Where to Buy appeared first on MedCity News.
Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression. The post Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder…
Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say. The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
The American Medical Association released a new report on Monday on pharmacy benefit managers. It explained that there is low competition among PBMs and high vertical integration with payers. The post AMA Report Details Low Competition in PBM Market appeared first on MedCity News.
That is the title of a paper from Costa-Font and Vilaplana-Prieto (2025). They find the the value is very large indeed. Relative to a country’s Gross Domestic Product (GDP), the value of IC [informal care] ranges between 4.2% in France and 0.85% in Germany. Such relative value declines as the country’s share of formal LTC…
In 2024, ACA enrollment (including Marketplace, Medicaid expansion, and BHP) reached 44 million, or 16.4% of the nonelderly U.S. population. From 2020-2024, enrollment in ACA coverage increased by over 60%.